If you are wondering whether CRISPR Therapeutics at around US$48.75 is a bargain or a concern, the key question is how its current share price lines up with what the business may be worth. The stock ...

After eight episodes of post-apocalypse insanity and plenty of irradiated creatures, Fallout wrapped up Season 2 with the season finale, “The Strip,” this week. Given that multiple characters are left ...

CRISPR/Cas-based biosensors offer an opportunity to quantify neuroinflammation in Parkinson’s disease, advancing diagnostics ...

Using a CRISPR-based biosensor platform, researchers have detected microRNA biomarkers of Alzheimer’s disease, with the ...

These two biotechs have a lot in common. Their differences are even more pronounced.

A recent study utilizing cryo-EM advances our understanding of how bacterial immune systems function and reveals new aspects ...

For decades, pest control has been an external intervention problem: the application of pesticides, the creation of barriers, or the release of sterilized insects, followed by a cycle. CRISPR gene ...

I was born in Washington, DC, in 1964, the oldest of three sisters, but the place that truly formed me as a scientist was Hilo, on the Big Island of Hawaii. Growing up there, far from the mainland ...

CRISPR Therapeutics has some promising and innovative pipeline candidates. The stock will soar if it can execute and deliver strong clinical and regulatory progress. CRISPR Therapeutics has lagged the ...

If you are wondering whether CRISPR Therapeutics at around US$53.52 is offering good value today, you are not alone. The stock often attracts investors who care about price versus potential. The share ...

Casgevy is starting to build some serious sales momentum. CRISPR Therapeutics also has a deep pipeline and healthy funding. The stock requires patience, but there is a visible path to a bright future.